Health News

Exelixis, Inc. and Bristol-Myers Squibb Company today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

Read more

Filed under: Pharmacy News
Tags: brain, cancer, Pharmacy

Related posts

• YM BioSciences’ nimotuzumab Phase II trials: FDA advises patient enrollment (0)
  YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated [...]
  
  
• YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC (0)
  YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll [...]
  
  
• Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers (0)
  A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology. Read [...]
  
  
• Update Of Long-Term Data On Brain Cancer Patients Receiving DCVax(R)-Brain Continues To Show Striking Improvements In Delay Of Disease And Survival (0)
  Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) ("NWBT" or the "Company") announced further long-term follow-up data, for the second half of 2008, from its prior Phase I and Phase I/II clinical trials with DCVax(R)-Brain in patients with Glioblastoma multiforme, the most rapid and lethal type of brain cancer. During the update [...]
  
  
• UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009 (0)
  Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New [...]